MedTrace Logo

Evaluation of the Effectiveness of the Nebulization Bronchodilators Under High Nasal Flow Humidified

NCT02812979 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-12-22

No results posted yet for this study

Summary

The principal objective is to show noninferiority of nebulized salbutamol through the high flow nasal system moistened AIRVO ™ 2 in terms of reversibility of airflow obstruction compared to nebulization by the usual method (spray mask).

Conditions

Interventions

DEVICE

Airvo2 with Aerogen Solo

Nebulization of salbutamol with Airvo 2 and Aerogen solo

DEVICE

Mask

Usual nebulization of salbutamol with mask

DEVICE

arm control Airvo2 without nebulization of salbutamol

Airvo2 with Aerogen Solo. No nebulization of salbutamol

Sponsors & Collaborators

  • University Hospital, Tours

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2018-04-27
Completion
2018-04-27

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02812979 on ClinicalTrials.gov